Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma)

•Lung cancer remains the most lethal tumor that urges better prognosis prediction.•CD155 and TIGIT are promising onco-immunologic molecules in lung cancer.•High expressions of CD155 and TIGIT indicate immunodeficiency and poor prognosis.•CD155 and TIGIT compose a prognosticating tool to stratify patients in LUAD. The interaction between CD155 and its high-affinity ligand TIGIT is being increasingly investigated in various solid tumors. However, the prognostic significance of CD155 and TIGIT in lung adenocarcinoma (LUAD) remains unclear. In this study, immunohistochemistry was applied in 334 LUAD cases to evaluate the expression of CD155 and TIGIT. Western blotting was conducted in 5 paired primary LUAD and adjacent normal lung tissues. Our results reveal that CD155 and TIGIT are overexpressed in LUAD tissues and that aberrant overexpression is closely correlated with poor clinical outcomes (P